Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 06, 2023

SELL
$8.86 - $25.04 $44 - $125
-5 Reduced 27.78%
13 $0
Q3 2022

Nov 09, 2022

SELL
$18.2 - $76.12 $764 - $3,197
-42 Reduced 70.0%
18 $0
Q2 2022

Aug 04, 2022

BUY
$36.28 - $75.29 $1,668 - $3,463
46 Added 328.57%
60 $3,000
Q1 2022

Aug 23, 2022

BUY
$69.73 - $142.9 $69 - $142
1 Added 7.69%
14 $1,000
Q1 2022

Apr 14, 2022

BUY
$69.73 - $142.9 $488 - $1,000
7 Added 116.67%
13 $1,000
Q4 2021

Feb 14, 2022

SELL
$134.56 - $217.97 $1,076 - $1,743
-8 Reduced 57.14%
6 $1,000
Q3 2021

Nov 10, 2021

BUY
$177.8 - $270.58 $711 - $1,082
4 Added 40.0%
14 $3,000
Q1 2021

May 05, 2021

SELL
$112.98 - $319.93 $15,817 - $44,790
-140 Reduced 93.33%
10 $2,000
Q3 2020

Nov 09, 2020

SELL
$79.44 - $178.51 $4,448 - $9,996
-56 Reduced 27.18%
150 $16,000
Q2 2020

Aug 06, 2020

BUY
$13.86 - $83.61 $2,855 - $17,223
206 New
206 $17,000
Q4 2019

Feb 07, 2020

SELL
$3.69 - $5.22 $184 - $261
-50 Closed
0 $0
Q2 2019

Aug 08, 2019

BUY
$4.93 - $12.2 $246 - $610
50 New
50 $0

Others Institutions Holding NVAX

About NOVAVAX INC


  • Ticker NVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,215,104
  • Market Cap $662M
  • Description
  • Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...
More about NVAX
Track This Portfolio

Track Glassman Wealth Services Portfolio

Follow Glassman Wealth Services and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Glassman Wealth Services, based on Form 13F filings with the SEC.

News

Stay updated on Glassman Wealth Services with notifications on news.